SONN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

FY2024Q4

28.50K

-22.66%

0.00

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Sonnet BioTherapeutics Holdings, Inc. (SONN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -80.56%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-80.56%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN.O) is -0.36, compared to its 5-year average forward P/E of -0.61. For a more detailed relative valuation and DCF analysis to assess Sonnet Biotherapeutics Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.61

Current PE

-0.36

Overvalued PE

-0.10

Undervalued PE

-1.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

80.12

Current PS

0.00

Overvalued PS

160.72

Undervalued PS

-0.48

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SONN News & Events

Events Timeline

No data

News

8.5

12-02Newsfilter

Hyperliquid Completes Merger with Sonnet, Stock to Trade on Nasdaq

8.5

12-02Newsfilter

Sonnet BioTherapeutics Shareholders Approve Merger with Hyperliquid Strategies Inc.

8.5

12-02Globenewswire

Sonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies

People Also Watch

Frequently Asked Questions

What is Sonnet Biotherapeutics Holdings Inc (SONN) stock price today?

The current price of SONN is 0 USD — it has decreased -146.03 % in the last trading day.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s business?

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

What is the price predicton of SONN Stock?

Wall Street analysts forecast SONN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SONN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s revenue for the last quarter?

Sonnet Biotherapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s earnings per share (EPS) for the last quarter?

Sonnet Biotherapeutics Holdings Inc. EPS for the last quarter amounts to -0.95 USD, decreased -82.94 % YoY.

What changes have occurred in the market's expectations for Sonnet Biotherapeutics Holdings Inc (SONN)'s fundamentals?

How many employees does Sonnet Biotherapeutics Holdings Inc (SONN). have?

Sonnet Biotherapeutics Holdings Inc (SONN) has 13 emplpoyees as of December 16 2025.

What is Sonnet Biotherapeutics Holdings Inc (SONN) market cap?

Today SONN has the market capitalization of 2.95M USD.